loperamide has been researched along with alvimopan anhydrous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Barker, WM; Belanger, S; Cassel, JA; Conway-James, NC; DeHaven, RN; DeHaven-Hudkins, DL; Dolle, RE; Le Bourdonnec, B; Little, PJ; O'Neill, TJ; Wiant, DD | 1 |
1 review(s) available for loperamide and alvimopan anhydrous
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for loperamide and alvimopan anhydrous
| Article | Year |
|---|---|
Novel trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines as mu opioid receptor antagonists with improved opioid receptor selectivity profiles.
Topics: Administration, Oral; Animals; Cell Membrane; Central Nervous System; Chromatography, High Pressure Liquid; Diprenorphine; Gastrointestinal Transit; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Loperamide; Mice; Molecular Structure; Piperidines; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Structure-Activity Relationship | 2008 |